pyrazolanthrone has been researched along with Thyroid Neoplasms in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cui, D; Xu, J; Zhao, Y | 1 |
| Chen, X; Chen, XJ; Gong, XH; Jiang, ZC; Wu, WJ; Zhou, Q | 1 |
| Fugazzola, L; Grassi, ES; Lábadi, Á; Negri, I; Persani, L; Vezzoli, V; Vitale, G | 1 |
| Bosari, S; Cirello, V; Colombo, C; Ferrero, S; Fugazzola, L; Grassi, ES; Persani, L; Ricca, D; Vaira, V; Vezzoli, V; Vicentini, L | 1 |
| Charpentier, E; El Btaouri, H; Greffe, Y; Martiny, L; Morjani, H | 1 |
| Bulgin, D; Mitsutake, N; Namba, H; Ohtsuru, A; Palona, I; Podtcheko, A; Rogounovitch, T; Saenko, V; Takakura, S; Yamashita, S | 1 |
6 other study(ies) available for pyrazolanthrone and Thyroid Neoplasms
| Article | Year |
|---|---|
Activation of CXCL5-CXCR2 axis promotes proliferation and accelerates G1 to S phase transition of papillary thyroid carcinoma cells and activates JNK and p38 pathways.
Topics: Animals; Anthracenes; Cell Line, Tumor; Cell Proliferation; Chemokine CXCL5; G1 Phase Cell Cycle Checkpoints; Humans; Imidazoles; MAP Kinase Signaling System; Mice; Mice, Nude; Phenylurea Compounds; Phosphorylation; Pyridines; Receptors, Interleukin-8B; Recombinant Proteins; Thyroid Cancer, Papillary; Thyroid Neoplasms; Xenograft Model Antitumor Assays | 2019 |
Downregulated LRRK2 gene expression inhibits proliferation and migration while promoting the apoptosis of thyroid cancer cells by inhibiting activation of the JNK signaling pathway.
Topics: Anthracenes; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Down-Regulation; Enzyme Activation; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; MAP Kinase Kinase 4; MAP Kinase Signaling System; Thyroid Neoplasms; Transfection | 2019 |
SP600125 has a remarkable anticancer potential against undifferentiated thyroid cancer through selective action on ROCK and p53 pathways.
Topics: Anthracenes; Cell Line, Tumor; Cell Proliferation; Histone Deacetylase 6; Histone Deacetylases; Humans; Protein Kinase Inhibitors; rho-Associated Kinases; Signal Transduction; Thyroid Neoplasms; Tumor Suppressor Protein p53 | 2015 |
Multicellular spheroids from normal and neoplastic thyroid tissues as a suitable model to test the effects of multikinase inhibitors.
Topics: Adenocarcinoma, Follicular; Adult; Aged; Aged, 80 and over; Anthracenes; Antineoplastic Agents; beta Catenin; Carcinoma, Papillary; Case-Control Studies; Cell Movement; Cell Proliferation; Female; Humans; Male; Middle Aged; Molecular Targeted Therapy; Phenotype; Protein Kinase Inhibitors; Protein Kinases; rho-Associated Kinases; Signal Transduction; Spheroids, Cellular; Thyroid Cancer, Papillary; Thyroid Gland; Thyroid Neoplasms; Tumor Cells, Cultured | 2017 |
Role of JNK/ATF-2 pathway in inhibition of thrombospondin-1 (TSP-1) expression and apoptosis mediated by doxorubicin and camptothecin in FTC-133 cells.
Topics: Activating Transcription Factor 2; Anthracenes; Apoptosis; Camptothecin; Caspase 3; Cell Line, Tumor; Cell Survival; Doxorubicin; Enzyme Activation; Gene Expression Regulation, Neoplastic; Humans; JNK Mitogen-Activated Protein Kinases; Phosphorylation; Signal Transduction; Sphingosine; Thrombospondin 1; Thyroid Neoplasms | 2011 |
Selective pharmacologic inhibition of c-Jun NH2-terminal kinase radiosensitizes thyroid anaplastic cancer cell lines via induction of terminal growth arrest.
Topics: Activating Transcription Factor 2; Anthracenes; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Combined Modality Therapy; DNA Repair; Humans; JNK Mitogen-Activated Protein Kinases; Radiation-Sensitizing Agents; Signal Transduction; Thyroid Neoplasms | 2006 |